Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021

Evan Suzman , Shu Wang , Jim C. Hu

Current Urology ›› 2025, Vol. 19 ›› Issue (6) : 429 -430.

PDF (122KB)
Current Urology ›› 2025, Vol. 19 ›› Issue (6) : 429 -430. DOI: 10.1097/CU9.0000000000000296
Letter to the Editor
research-article

Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021

Author information +
History +
PDF (122KB)

Cite this article

Download citation ▾
Evan Suzman, Shu Wang, Jim C. Hu. Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021. Current Urology, 2025, 19(6): 429-430 DOI:10.1097/CU9.0000000000000296

登录浏览全文

4963

注册一个新账户 忘记密码

Acknowledgments

None.

Statement of ethics

Not applicable.

Conflict of interest statement

SW is a member of early career editorial board of Current Urology and confirms no involvement in any stage of this article's review process, ensuring unbiased editorial decision-making. JCH receives research support from Frederick and the Theresa Dow Wallace Fund of the New York Community Trust. JCH receives salary support from NIH R01 CA241758, R01 CA259173, R01 CA273031, PCORI CER-2019C1-15682, and CER-2019C2-17372, and the Prostate Cancer Foundation Challenge Award. No other relationships or activities appear to have influenced the submitted work.

Funding source

None.

Author contributions

ES, SW: Writing - original;

ES, SW, JCH: Data analysis and interpretation, and critical revision of the manuscript;

JCH: Concept, methodology, and supervision.

Data availability

ES and SW had full access to all the data in this study and take responsibility for the integrity of the data and accuracy of the data analysis.

References

[1]

Vickers AJ, Cooperberg MR, Eggener SE. Removing the designation of cancer from grade group 1 disease will do more good than harm. Eur Urol 2023; 83(4):304-306.

[2]

Monda SM, Demus T, Jaime-Casas S, et al. Trends in surgical overtreatment of prostate cancer. JAMA Oncol 2025;e250963.

[3]

Borregales LD, DeMeo G, Gu X, et al. Grade migration of prostate cancer in the United States during the last decade. J Natl Cancer Inst 2022; 114(7):1012-1019.

[4]

Soerensen SJC, Li S, Langston ME, Fan RE, Rusu M, Sonn GA. Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022. Prostate Cancer Prostatic Dis 2025; 28(2):519-522.

[5]

Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional adoption of commercial gene expression testing for prostate cancer. JAMA Oncol 2021; 7(1):52-58.

AI Summary AI Mindmap
PDF (122KB)

245

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/